Cannabigerolic acid (CBGA) is a cannabinoid precursor found in cannabis plants. Its use for acne is primarily supported by preclinical scientific research rather than traditional or historical use. Several in vitro studies have examined the potential of cannabinoids, including CBGA and its decarboxylated form CBG, in influencing sebocyte function and reducing inflammation associated with acne. For example, a 2016 study published in the journal Experimental Dermatology showed that CBG, derived from CBGA, inhibited excessive lipid production (sebogenesis) and exerted anti-inflammatory effects in human sebocyte cultures—both key factors in acne development. While these findings suggest a possible therapeutic role, direct studies on CBGA itself are limited, and most available research has focused more on cannabidiol (CBD) and its anti-acne properties. Clinical trials in humans are lacking for CBGA specifically, and there is no regulatory approval for its use in acne treatment. In summary, there is preliminary scientific evidence from laboratory studies suggesting CBGA may help address mechanisms underlying acne, but evidence is currently limited in both quality and quantity, and there is no established historical use.